Apellis Pharmaceuticals (NASDAQ:APLS) Issues Earnings Results, Beats Expectations By $0.86 EPS

Apellis Pharmaceuticals (NASDAQ:APLS) announced its quarterly earnings data on Tuesday. The company reported $0.47 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.86, Briefing.com reports. Apellis Pharmaceuticals had a return on equity of 9.31% and a net margin of 2.23%.The company had revenue of $199.91 million for the quarter, compared to analyst estimates of $199.28 million. During the same quarter in the previous year, the company earned ($0.29) EPS. The firm’s revenue for the quarter was down 5.9% compared to the same quarter last year.

Here are the key takeaways from Apellis Pharmaceuticals’ conference call:

• Empaveli achieved >5% market penetration after its first full quarter with 267 cumulative patient start forms, and management believes it could be used by up to 50% of the ~5,000 U.S. C3G/IC‑MPGN patients over time — signaling a potentially blockbuster launch.
• Syfovre showed underlying demand (total injections up ~17% YoY) but full‑year revenue was modestly down due to elevated free‑goods use; co‑pay assistance reopening and planned rollouts of a prefilled syringe and AI‑enabled OCTF are positioned to support renewed growth in 2027.
• The pipeline advanced meaningfully — pivotal trials for Empaveli in FSGS and delayed graft function are underway, a Syfovre + APL‑3007 Phase 2 (top‑line 2027) is progressing, and APL‑9099 (a first‑in‑class base‑editing FcRn program) targets an IND in H2 2026 — all supporting long‑term upside.
• FY2025 revenue was $1.0B (Q4 $200M) including a one‑time $275M Sobi payment; the company ended the year with $466M cash, expects modestly higher 2026 operating expenses, and has a $94M convertible debt maturing September 2026 that it is evaluating options to address.
• New five‑year GALE post‑hoc data showed Syfovre delayed GA progression by about 1.5 years in non‑subfoveal patients versus sham, reinforcing its long‑term efficacy and the company’s message to drive earlier treatment adoption.

Apellis Pharmaceuticals Stock Down 1.1%

Shares of NASDAQ:APLS opened at $21.18 on Thursday. Apellis Pharmaceuticals has a 12-month low of $16.10 and a 12-month high of $30.48. The stock’s 50-day moving average price is $23.13 and its two-hundred day moving average price is $23.83. The company has a current ratio of 3.54, a quick ratio of 3.10 and a debt-to-equity ratio of 0.90. The firm has a market cap of $2.68 billion, a price-to-earnings ratio of 19.76 and a beta of 0.26.

Key Stories Impacting Apellis Pharmaceuticals

Here are the key news stories impacting Apellis Pharmaceuticals this week:

• Positive Sentiment: Q4 earnings beat — Apellis reported $0.47 EPS, topping consensus (a loss) and narrowly beating revenue estimates; this outperformance supports near-term sentiment. Article Title
• Positive Sentiment: Empaveli strength — Management highlighted a ~50% surge in Empaveli sales tied to a new-indication launch, a growth driver offsetting weakness in Syfovre. Article Title
• Positive Sentiment: HC Wainwright bullish — The firm raised its target to $48 and issued a long-term FY2030 EPS projection of $1.97, keeping a Buy rating; this is a constructive analyst signal for upside potential. Article Title
• Neutral Sentiment: Citigroup trimmed its target slightly to $44 but maintained a Buy — limited directional impact given the continued Buy stance. Article Title
• Neutral Sentiment: Full earnings materials and transcripts are available for investor review (useful for judging pipeline commentary and margin dynamics). Article Title
• Neutral Sentiment: Short-interest postings in the feeds show zero/NaN values (likely data/reporting error) and provide no actionable signal.
• Negative Sentiment: RBC cut its target to $21 and set a Sector Perform — a more cautious view that could pressure sentiment. Article Title
• Negative Sentiment: Wedbush lowered its target to $18 and moved to Neutral — another downgrade weighing on near-term investor appetite. Article Title
• Negative Sentiment: Top-line pressure — total revenue fell year-over-year and Syfovre sales slipped ~8%, highlighting dependence on product mix and the need for sustained Empaveli growth to offset declines. Article Title

Insider Transactions at Apellis Pharmaceuticals

In other Apellis Pharmaceuticals news, insider Mark Jeffrey Delong sold 3,371 shares of the stock in a transaction on Thursday, January 22nd. The shares were sold at an average price of $21.77, for a total transaction of $73,386.67. Following the transaction, the insider directly owned 78,353 shares in the company, valued at $1,705,744.81. This represents a 4.12% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Caroline Baumal sold 2,797 shares of the business’s stock in a transaction on Thursday, January 22nd. The shares were sold at an average price of $21.77, for a total transaction of $60,890.69. Following the sale, the insider owned 86,527 shares of the company’s stock, valued at approximately $1,883,692.79. The trade was a 3.13% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 120,537 shares of company stock valued at $2,608,532 in the last quarter. Insiders own 6.50% of the company’s stock.

Institutional Investors Weigh In On Apellis Pharmaceuticals

Several large investors have recently modified their holdings of the stock. Quarry LP raised its holdings in shares of Apellis Pharmaceuticals by 220.4% during the third quarter. Quarry LP now owns 16,022 shares of the company’s stock worth $363,000 after acquiring an additional 11,022 shares in the last quarter. Twinbeech Capital LP increased its position in Apellis Pharmaceuticals by 47.3% in the 4th quarter. Twinbeech Capital LP now owns 13,152 shares of the company’s stock worth $330,000 after purchasing an additional 4,225 shares during the last quarter. Freestone Grove Partners LP purchased a new stake in shares of Apellis Pharmaceuticals during the 4th quarter worth about $315,000. Bridgefront Capital LLC purchased a new stake in shares of Apellis Pharmaceuticals during the 4th quarter worth about $285,000. Finally, Franklin Resources Inc. acquired a new stake in shares of Apellis Pharmaceuticals during the 4th quarter valued at about $284,000. 96.29% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on APLS shares. William Blair reaffirmed an “outperform” rating on shares of Apellis Pharmaceuticals in a research note on Monday, December 15th. Citigroup lowered their target price on shares of Apellis Pharmaceuticals from $45.00 to $44.00 and set a “buy” rating on the stock in a research report on Wednesday. JPMorgan Chase & Co. reduced their price target on shares of Apellis Pharmaceuticals from $40.00 to $36.00 and set an “overweight” rating for the company in a research report on Wednesday, November 5th. Needham & Company LLC decreased their price target on Apellis Pharmaceuticals from $29.00 to $28.00 and set a “buy” rating on the stock in a research note on Tuesday, January 13th. Finally, HC Wainwright upped their price target on Apellis Pharmaceuticals from $45.00 to $48.00 and gave the stock a “buy” rating in a report on Wednesday. Twelve analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Apellis Pharmaceuticals presently has a consensus rating of “Hold” and an average target price of $32.61.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, traded as NASDAQ:APLS, is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the complement cascade for the treatment of rare and debilitating diseases. The company’s research and development efforts center on modulating complement proteins to address a range of ophthalmologic, hematologic and renal conditions. Apellis leverages its proprietary compstatin technology platform to design targeted inhibitors intended to improve patient outcomes and quality of life.

The company’s lead marketed product, Syfovre (pegcetacoplan), is an intravitreal complement C3 inhibitor approved for geographic atrophy secondary to age-related macular degeneration, with ongoing investigations in other retinal disorders.